After the stock markets ended with another flat day on ASX, four stock that came under discussion are from health care and energy sector. The industries are boosted with new technologies coming in, here are some discussion points for these stocks.
BIOTRON LIMITED (ASX: BIT) –
The company has recently secured with CPS capital group Pvt. Ltd a $4.7 million underwriting agreement. Also, the cash and cash equivalents are of $1,543,002 at the end of June 30, 2018, which is lower compared to the cash of $1,987,384 in 2017. The EPS is reflecting on the losses made by the company which is around -0.004 AUD. The directors do not recommend dividends to be paid or declared for this financial year or previous year. The stock of Biotron Limited traded at a market price of $0.255, as at October 22, 2018, and over the last twelve months period it has witnessed a performance change of a staggering 1582.63%.
RESAPP HEALTH LIMITED (ASX: RAP) –
The net loss for the year ended 30 June 2018 was $6,533,435 compared with a net loss of $10,032,750 for the previous year. Also, the Company had a net asset position as at 30 June 2018 of $5,542,516 as compared to 2017 of $11,349,067. No amounts have been paid or declared by way of dividend by the Group since the end of the previous financial year and the Directors do not recommend the payment of any dividend. THE EPS of the stock is currently negative 0.010 AUD reflecting restricted growth. The stock of ResApp traded at a market price of $0.220, as at October 22, 2018, and over the last twelve months period it has witnessed a performance change of a staggering 214.29%.
STRIKE ENERGY LIMITED (ASX: STX) –
Strike and UIL Energy Limited have entered into a binding Takeover Implementation Deed will make a conditional off-market takeover offer to acquire all of the issued shares of UIL Energy at an offer price of 0.485 Strike Energy shares for each UIL Energy ordinary share. Through a share placement to support the piloting activities of the jaws well, in August 2018, Strike raised $2.9 million. The profit after tax decreased marginally from $2.3 million to $2.2 million which is mainly due to the decrease in income tax benefit received. The stock of strike limited traded at a market price of $0.145, as at October 22, 2018, and over the last twelve months period it has witnessed a performance change of a staggering 107.14%.
SUDA PHARMACEUTICALS LTD (ASX: SUD) –
The global drug delivery technologies market is expected to grow from $1,179.20 billion to $1,669.40 billion at a CAGR of 7.2% from the year 2016-2021. The group reported annual revenue from continuing operations of $425,864 as at June 30, 2018 as compared to the previous year period of June 30, 2017 of $444,029. The total cash and cash equivalent at the end of the financial year is at $98,125. No amounts have been paid or declared by way of dividend by the Group since the end of the previous financial year and the Directors do not recommend the payment of any dividend. The stock of Suda limited surged by 42.857% to trade at a market price of $0.010, as at October 22, 2018, and over the last one-month period it has witnessed a performance change of a staggering 40.00%.
Dividend Stocks To Buy
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.